AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Cellectar Biosciences INC NEW
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SNWCK2
1.22▲ 0.05 (4.27%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.17
Day's Range
1.14 – 1.22
52-Week Range
1.12 – 4.70
Volume
55.9K
Avg Volume
133.5K
Share Statistics
Shares Outstanding
Employees
11
Exchange
XNAS
Listed
2005-04-19
Share count as of August 11, 2026

Cellectar Biosciences INC NEW (CLRB) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Cellectar Biosciences INC NEW (CLRB)
What is Cellectar Biosciences INC NEW's Market Cap?
Cellectar Biosciences INC NEW's Market Cap is $11.5M, based on as-reported figures from SEC (XBRL) filings.
What is Cellectar Biosciences INC NEW's Enterprise Value?
Cellectar Biosciences INC NEW's Enterprise Value is -$22.5M, based on as-reported figures from SEC (XBRL) filings.
What is Cellectar Biosciences INC NEW's EV / EBITDA?
Cellectar Biosciences INC NEW's EV / EBITDA is 1.0×, based on as-reported figures from SEC (XBRL) filings.
What is Cellectar Biosciences INC NEW's Net Income (TTM)?
Cellectar Biosciences INC NEW's Net Income (TTM) is -$22.3M, based on as-reported figures from SEC (XBRL) filings.
What is Cellectar Biosciences INC NEW's EBITDA?
Cellectar Biosciences INC NEW's EBITDA is -$23.3M, based on as-reported figures from SEC (XBRL) filings.
What is Cellectar Biosciences INC NEW's Diluted EPS (TTM)?
Cellectar Biosciences INC NEW's Diluted EPS (TTM) is -2.36, based on as-reported figures from SEC (XBRL) filings.
What is Cellectar Biosciences INC NEW's Net Debt?
Cellectar Biosciences INC NEW's Net Debt is -$34.0M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CLRBAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
OPERATING EXPENSES:
Research and development
General and administrative
Total operating expenses
LOSS FROM OPERATIONS
OTHER INCOME (EXPENSE):
Gain (loss) on valuation of warrants
Interest income
Total other income (expense)
NET LOSS
NET LOSS PER SHARE - BASIC (In dollars per share)
NET LOSS PER SHARE - DILUTED (In dollars per share)